Mylan’s Biogenerics Strategy: Build Standards From Europe, Be Financially Cautious
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic firm is counting on Global Biologics Head Patrick Vink’s experience as Sandoz biopharma head to lead the firm into the follow-on biologics marketplace.
You may also be interested in...
Teva/Barr Combination Creates Biosimilar Force
Teva’s $7.46 billion acquisition of Barr will result in a generics powerhouse, expanding U.S. leadership and geographic footprint.
Waxman And Hatch Foresee Follow-on Biologics Bill Regaining Momentum – In 2009
Closing window for congressional action, lack of House consensus and Sen. Kennedy’s absence among reasons the issue will be held until next year, they suggest.
FDA Clears Omnitrope; Product Is Not The Process, But Nor Is It A Pathway
Sandoz' approval for the first follow-on version of a human growth hormone product relies on data from a Phase III clinical program that studied 89 pediatric patients